MDL Judge Refuses to Dismiss Fraud-Based Claims Against Valsartan Manufacturers



DOCUMENTS
  • Order


CAMDEN, N.J. — The New Jersey federal judge overseeing the MDL docket for cases alleging contamination of the blood pressure drug valsartan has refused to dismiss the fraud-based claims against the manufacturing defendants, ruling that they were pled with sufficient particularity.

However, in the Jan. 29 order, Judge Robert B. Kugler of the U.S. District Court for the District of New Jersey dismissed without prejudice the fraud-based claims against the wholesaler and pharmacy defendants, ruling that they were too conclusory to fulfill Rule 9(b)’s particularity requirement.

Originally marketed under the brand name Diovan, valsartan is a prescription drug primarily used …






UPCOMING CONFERENCES




HarrisMartin's Webinar Series: 3M Combat Arms Earplugs - Litigating with the Government as a Witness

March 12, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS



HarrisMartin's Webinar Series: Natural Disaster Litigation - Insurance and Beyond - Winter Storm Uri and Hurricane Sally

March 09, 2021 - Haddonfield, NJ
HarrisMartin Webinar Series

MORE DETAILS